🧠 Neurofibromatosis type 1 (NF1) is a complex genetic disorder marked by tumor growth along nerves, including plexiform neurofibromas (PN). Treatment options have historically been limited, but exciting progress with MEK inhibitors is opening the door to more effective, systemic care. 🔬 The ANA is excited to share this new educational activity from PeerView offering practical guidance on integrating MEK inhibitors into NF1 care, optimizing treatment strategies, and improving coordination across specialties to support lifelong care. Explore expert-led insights into emerging targeted therapies for both pediatric and adult patients with NF1-PN, and learn how to strengthen multidisciplinary collaboration for better outcomes. 🎥 Watch now: https://bit.ly/4hBrBDv (fb)

📢 New at #ANA2025: ANA Clinical Trials Course Ready to elevate your impact in clinical research? Join us for a full-day, hands-on course designed for academic neurologists and neuroscientists at every career stage. From trial design basics to advanced strategies, gain the skills, insights, and tools you need to succeed in today’s research landscape. 🔬 Build your foundation 📊 Strengthen your trial design 🤝 Connect with expert faculty ⏳ Space is limited! Add the course to your ANA2025 registration today! Learn More: https://2025.myana.org/program/ana-clinical-trials-course/ #ClinicalTrials #ClinicalResearch #Neurology #AcademicNeurology (fb)